Collegium Pharmaceutical (COLL) Price Target Raised to $27.00 at Jefferies Group
Collegium Pharmaceutical (NASDAQ:COLL) had its target price hoisted by Jefferies Group to $27.00 in a report released on Tuesday, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.36 EPS.
Other analysts have also issued research reports about the company. HC Wainwright began coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a buy rating and a $21.00 target price on the stock. Zacks Investment Research raised Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Monday, August 14th. Piper Jaffray Companies set a $19.00 target price on Collegium Pharmaceutical and gave the company a buy rating in a research report on Wednesday, November 29th. Finally, Needham & Company LLC reissued a buy rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $23.50.
Collegium Pharmaceutical (NASDAQ COLL) traded down $0.64 on Tuesday, reaching $17.70. The company had a trading volume of 1,342,032 shares, compared to its average volume of 1,208,443. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.92.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.13) earnings per share. equities analysts anticipate that Collegium Pharmaceutical will post -2.56 EPS for the current fiscal year.
In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the sale, the insider now directly owns 28,513 shares in the company, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders have sold 58,630 shares of company stock worth $924,360 in the last ninety days. Corporate insiders own 25.76% of the company’s stock.
Several institutional investors have recently bought and sold shares of COLL. Sectoral Asset Management Inc increased its position in shares of Collegium Pharmaceutical by 41.4% during the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after acquiring an additional 529,503 shares during the period. Citadel Advisors LLC increased its position in shares of Collegium Pharmaceutical by 773.8% during the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after acquiring an additional 481,771 shares during the period. Macquarie Group Ltd. increased its position in shares of Collegium Pharmaceutical by 37.1% during the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock worth $13,995,000 after acquiring an additional 302,892 shares during the period. Prudential Financial Inc. increased its position in shares of Collegium Pharmaceutical by 62.8% during the third quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock worth $5,843,000 after acquiring an additional 214,860 shares during the period. Finally, Pura Vida Investments LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter worth $1,229,000. 79.98% of the stock is currently owned by institutional investors and hedge funds.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.